Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 7/20 | 0.61 |
| ▸ | CA1 | P00915 | 6/20 | 0.61 |
| ▸ | CA9 | Q16790 | 4/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 3/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4411479 | 0.87 | CNR2 (0.81) | CNR2TSHRSMPD1 | |
| SCHEMBL4407777 | 0.86 | CNR2 (1.00) | CNR2SMPD1 | |
| SCHEMBL4410346 | 0.85 | CNR2 (0.81) | CNR2SMPD1MAPT | |
| SCHEMBL4410378 | 0.85 | CNR2 (0.98) | CNR2SMPD1 | |
| SCHEMBL4409426 | 0.85 | CNR2 (0.98) | CNR2SMPD1 | |
| SCHEMBL4410751 | 0.84 | CNR2 (0.80) | CNR2TSHRSMPD1 | |
| SCHEMBL4418690 | 0.84 | CNR2 (0.96) | CNR2SMPD1MAPT | |
| SCHEMBL4417003 | 0.83 | CNR2 (0.75) | CNR2USP2SMPD1MAPT | |
| SCHEMBL4406738 | 0.83 | CNR2 (0.78) | CNR2TSHRSMPD1 | |
| SCHEMBL4551660 | 0.83 | CNR2 (0.94) | CNR2SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0887340-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 1998-12-30 | — | — | EP | claimed |
| EP-2130820-A1 | Antipruritics | SHIONOGI & CO., LTD. (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| WO-2002047691-A9 | PROTECTION OF NEURONS AGAINST GLUTAMATE-INDUCED DAMAGE IN GLAUCOMA AND OTHER CONDITIONS | AYOUB GEORGE S (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2002047691-A1 | PROTECTION OF NEURONS AGAINST GLUTAMATE-INDUCED DAMAGE IN GLAUCOMA AND OTHER CONDITIONS | AYOUB GEORGE S (US) | 2002-06-20 | — | — | WO | disclosed |
| US-6017919-A | Compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2000-01-25 | — | — | US | disclosed |
| EP-0887340-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 1998-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | CNR2 2/4885TSHR 773/4885NPSR1 19/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | CNR2 2/4885TSHR 1644/4885NPSR1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.